MeiraGTx (NASDAQ: MGTX) — Perfil da empresa, notícias e dados financeiros
MeiraGTx develops groundbreaking gene therapies for high unmet medical needs, focusing on eye diseases and neurodegenerative conditions.

MeiraGTx
MeiraGTx (NASDAQ:MGTX) is a biotechnology company dedicated to developing cutting-edge gene therapy solutions for patients suffering from diseases of high unmet medical need. The primary focus of the company is on the development of treatments for eye diseases, salivary gland conditions, and neurodegenerative diseases. Throughout its operations, MeiraGTx aims to leverage its unique gene therapy platforms to create transformative treatments that can significantly improve the quality of life for patients worldwide. Their projects span from early discovery to late-stage development, emphasizing innovation, patient safety, and efficacy. By pursuing a deep understanding of genetic diseases, MeiraGTx's objective is to pioneer novel gene therapy solutions that address the root causes of these conditions, with the ultimate goal of delivering life-changing treatments to the patients and communities they serve.
Resumo
Operações
Produtos e/ou serviços de MeiraGTx
- Gene Therapy Development Platform: MeiraGTx develops methods for delivering gene therapies into patients' cells.
- Gene Therapy for Rare Eye Diseases: They create gene therapies to treat inherited conditions affecting vision.
- Gene Therapy for Blood Disorders: MeiraGTx researches gene therapies for diseases affecting blood clotting mechanisms.
- Gene Therapy for Liver Diseases: They are developing gene therapies to address genetic conditions impacting the liver.
- Preclinical Gene Therapy Research: MeiraGTx conducts early-stage research on gene therapies for various diseases.
- Gene Therapy Pipeline Development: They have a pipeline of potential gene therapies in development for various conditions.
equipe executiva do MeiraGTx
- Alexandria ForbesCEO, President & Director
- Richard Brian GirouxCOO & CFO
- Robert K. ZeldinChief Medical Officer
- Robert J. WollinGeneral Counsel & Secretary
- Stuart NaylorChief Scientific Officer of Ophthalmology
- Michel MichaelidesHead of Clinical Ophthalmology
- Christine Elise SheehySenior Vice President of Global Integration
- Tim RandallSenior Vice President of Risk & Internal Controls
- David RubinsteinSenior Vice President of Business Development
- Tassos GeorgiadisSenior Vice President of Discovery & Preclinical Development
Principais indicadores financeiros
Resultados divulgados pela MeiraGTx , em USD.
- Cap. de mercado
- 936,4 mi
- Receita (TTM)
- 397,5 mi
- P/L
- 11.2
- LPA (diluído, TTM)
- 0.9
- Dividend yield
- —
- Margem de lucro
- 19.9%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 81,4 mi | -106 mi | -114,2 mi | |
| 33,3 mi | -164,2 mi | -147,8 mi | |
| 14 mi | -137,1 mi | -84 mi | |
| 15,9 mi | -116,4 mi | -129,6 mi |